A group advocating for the 340B Drug Discount Program examined the widely held belief that health care organizations enrolled in the controversial federal program receive significantly higher reimbursement for drugs than institutions that do not take part in the program.
Federal prosecutors earlier this week filed a complaint against the Memphis Methodist health system, taking over a qui tam action initially filed by private whistleblowers, who alleged that Methodist’s six-year arrangement with West Clinic, an oncology private practice, violated the Anti-Kickback Statute and the False Claims Act.
